Novartis strategic business transformations were summarized for investors at 2024 J.P. Morgan Healthcare
This video highlights the major business changes that moved Novartis into a pure-play innovative medicines company. Our CEO Vas Narasimhan explains the major changes in ownership and spin offs, and how this has improved the financial profile of the company.
*This video uses audio from the webcasted event.*
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: go.novartis.social/49012mq
Full presentation here: go.novartis.social/47TQ8ho
Novartis JPM HC 2024 Coverage: go.novartis.social/3vUQwih
Investor Relations: go.novartis.social/3vVuP1H
Investor Events: go.novartis.social/49hD7zf
Novartis Strategy: go.novartis.social/3ugzPgH
Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/47TQ8ho
The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website go.novartis.social/3SjiU5h.
Learn more: go.novartis.social/3vUQwih